Conference Coverage: San Antonio Breast Cancer Symposium
SABCS 2025
- 1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years
- Anixa Biosciences Announces Positive Ph 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants
- Arvinas Presents data from the Vepdegestrant (ARV-471) Clinical Development Program
- Atossa Therapeutics Presents Four Abstracts Highlighting (Z)-Endoxifen Research
- BioNTech and BMS Present First Global Ph 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced TNBC
- BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data
- Carrick Therapeutics Announces Positive Results from Ph 2 Randomized Trial of Samuraciclib in Combination with Fulvestrant in Patients with HR+ve, HER2-neg Advanced Breast Cancer
- Celcuity Presents Updated Results from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial
- CytoDyn Presents Prolonged Survival Data on Leronlimab in Metastatic TNBC
- Immutep to Present New Data from AIPAC-003 Ph 2
- Intensity Therapeutics Presents Two Posters
- Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib’s Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+
- Marengo Presents Initial Results from Invikafusp Alfa and TRODELVY® Combination Study, STARt-002
- Menarini Group Presents Elacestrant (ORSERDU®) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC)
- Olema Oncology Presents Trial-in-Progress Poster for Phase 3 OPERA-02 Trial of Palazestrant Plus Ribociclib
- Oncotelic and Sapu Nano Announce DeciparticleTM Led Biomarker Framework Identifying Tumors Most Likely to Respond to IV Sapu003
- Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations
- Roche’s giredestrant reduced risk of invasive disease recurrence or death by 30% in ER-positive early-stage breast cancer
- TUKYSA Added to 1L Maintenance Therapy Extends mPFS by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer
- Updated data for Lilly’s Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer